Spero Therapeutics grants options and RSUs to CMO
Spero Therapeutics, Inc. reported that Chief Medical Officer Debra Zack received two equity awards on August 3, 2026.
Rhea-AI Filing Summary
Spero Therapeutics, Inc. reported that Chief Medical Officer Debra Zack received two equity awards on August 3, 2026. She was granted 162,311 RSUs under the 2019 Stock Incentive Plan, vesting in four equal annual installments beginning August 3, 2027, and stock options for 324,675 shares of common stock at an exercise price of $1.5400 per share, vesting 25% on August 3, 2027 with the remainder vesting in 36 equal monthly installments, all subject to continued service. The filing indicates these transactions were made pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Grant/Award: 486,986 shares
Grant/Award
2 txns
Insider
Zack Debra
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) F2 | 324,675 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 162,311 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 324,675 contracts (Direct);
Common Stock — 162,311 shares (Direct)
Footnotes (2)
- F1. Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2019 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 3, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
- F2. The shares underlying this option vest as to 25% on August 3, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
RSU grant: 162,311 shares
Stock option grant: 324,675 shares
Option exercise price: $1.5400 per share
+3 more
6 metrics
RSU grant
162,311 shares
Restricted stock units granted to Chief Medical Officer on 2026-08-03
Stock option grant
324,675 shares
Stock options awarded to Chief Medical Officer on 2026-08-03
Option exercise price
$1.5400 per share
Conversion or exercise price of the stock option grant
Option initial vesting portion
25 %
Portion of option vesting on August 3, 2027
RSU vesting schedule
4 annual installments
RSUs vest in four equal annual installments beginning August 3, 2027
Remaining option vesting period
36 monthly installments
Remaining options vest in 36 equal monthly installments after August 3, 2027
Key Terms
restricted stock units ("RSUs"), 2019 Stock Incentive Plan, Stock option (right to buy), vesting
4 terms
restricted stock units ("RSUs") financial
"Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2019 Stock Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Stock Incentive Plan financial
"RSUs granted to Reporting Person under Issuer's 2019 Stock Incentive Plan."
Stock option (right to buy) financial
"security_title: Stock option (right to buy) with underlying Common Stock."
vesting financial
"Each RSU represents the right to receive one share of common stock upon vesting."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Spero Therapeutics (SPRO) grant to Chief Medical Officer Debra Zack?
Debra Zack received 162,311 RSUs and stock options for 324,675 shares of common stock. The options carry a $1.5400 exercise price and both awards were granted on August 3, 2026.
How do the RSUs granted by Spero Therapeutics (SPRO) to Debra Zack vest?
The 162,311 RSUs vest in four equal annual installments beginning on August 3, 2027. Each RSU represents the right to receive one share of common stock, subject to Zack’s continued service through each vesting date.
What are the vesting terms of Debra Zack’s new stock options at Spero Therapeutics (SPRO)?
The 324,675 stock options vest 25% on August 3, 2027, with the remaining 75% vesting in 36 equal monthly installments. Vesting is conditioned on Debra Zack’s continued service with the company.
What is the exercise price and expiration for Debra Zack’s Spero Therapeutics (SPRO) stock options?
The awarded stock options have an exercise price of $1.5400 per share and are exercisable for 324,675 shares of common stock. They are scheduled to expire on August 3, 2036, assuming they have vested and are not forfeited earlier.
Under which plan were Debra Zack’s equity awards from Spero Therapeutics (SPRO) granted?
Both the RSUs and the stock options were granted under Spero Therapeutics’ 2019 Stock Incentive Plan. This plan governs the terms of the awards, including vesting conditions tied to Debra Zack’s continued service.
Were Debra Zack’s Spero Therapeutics (SPRO) equity awards reported under a Rule 10b5-1 trading plan?
Yes. The filing’s Rule 10b5-1 checkbox is marked, indicating the reported equity awards were made pursuant to a Rule 10b5-1 trading plan, which pre-establishes transaction terms under SEC rules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
